1-(3-Hydroxy-2-phosphonomethoxypropyl)-4-aminopyrimidin-2(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(3-Hydroxy-2-phosphonomethoxypropyl)-4-aminopyrimidin-2(1H)-one
• 英文别名: [1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
• 化学式: C₈H₁₄N₃O₆P
• 分子量: 279.19
• InChiKey: VWFCHDSQECPREK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  146
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Anti-virus compounds
  申请人：——

  公开号：US20040044069A1

  公开（公告）日：2004-03-04

  This invention features a method for treating infection by herpesvirus. The method includes administering to a subject in need thereof an effective amount of an arylnaphthalene compound of formula (I): 1 Each of R 1 and R 2 , independently is R or C(O)R; or R 1 and R 2 taken together is (CH 2 ) m ; each of R 3 , R 4 , and R 5 , independently, is R, OR, C(O)R, or OC(O)R; or any two of R 3 , R 4 , and R 5 taken together is O(CH 2 ) n O; Ar is aryl; each of Z 1 and Z 2 , independently, is CH 2 or C(O); and each of R 6 and R 7 , independently, is R, OR, SR, or NRR′; or R 6 and R 7 taken together is O, S, or NR; in which each of R and R′, independently, is H, alkyl, (CH 2 ) o -aryl, (CH 2 ) p -heteroaryl, cyclyl, or heterocyclyl; each of m and n, independently, is 1, 2, 3, or 4; and each of o and p, independently, is 0, 1, 2, 3, 4, 5, or 6.

  这项发明涉及一种治疗单纯疱疹病毒感染的方法。该方法包括向需要的受试者施用式(I)的芳基萘化合物的有效量：1每个R1和R2，在独立情况下为R或C(O)R；或R1和R2一起为(CH2)m；每个R3、R4和R5，在独立情况下为R、OR、C(O)R或OC(O)R；或R3、R4和R5中的任意两个一起为O( )nO；Ar为芳基；每个Z1和Z2，在独立情况下为 或C(O)；每个R6和R7，在独立情况下为R、OR、SR或NRR′；或R6和R7一起为O、S或NR；其中每个R和R′，在独立情况下为H、烷基、( )o-芳基、( )p-杂环芳基、环烷基或杂环烷基；每个m和n，在独立情况下为1、2、3或4；每个o和p，在独立情况下为0、1、2、3、4、5或6。
• Substituted Phosphate Esters of Nucleoside Phosphonates
  申请人：Hostetler Karl Y.

  公开号：US20090156545A1

  公开（公告）日：2009-06-18

  Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the phosphonate nucleoside of interest to alkyloxyalkyl-phosphate or alkyl-phosphate in a phosphate-phosphono anhydride linkage to provide a modified nucleoside phosphonate drug.

  本文提供了用于治疗、预防或改善与病毒感染和/或细胞增殖有关的各种医学疾病的化合物和组合物。所提供的化合物是通过将感兴趣的膦酸核苷连接到烷氧基烷基磷酸酯或烷基磷酸酯中的磷酸酯-膦酸酐连接处，从而提供一种修饰的核苷酸膦酸药物获得的。
• EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
  申请人：Institut Gustave Roussy (IGR)

  公开号：EP2371369A1

  公开（公告）日：2011-10-05

  The application relates to a combination of biologically active compounds comprising at least one antiviral agent and at least one EGFR antagonist, for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of malignant or pre-malignant neoplasms, preferably of solid malignant or pre-malignant neoplasms.

  该申请涉及一种生物活性化合物的组合，其中包括至少一种抗病毒剂和至少一种EGFR拮抗剂，用于同时、分开或顺序使用，用于治疗和/或预防和/或缓解恶性或癌前病变，最好是固体恶性或癌前病变。
• [EN] CIDOFOVIR PEPTIDE CONJUGATES AS PRODRUGS<br/>[FR] CONJUGUES PEPTIDIQUES DE CIDOFOVIR UTILISES COMME PROMEDICAMENTS
  申请人：UNIV SOUTHERN CALIFORNIA LA

  公开号：WO2006014429A2

  公开（公告）日：2006-02-09

  Cidofovir-based compounds having an amino acid, dipeptide or tripeptide attached to a cidofovir or cyclic cidofovir framework. The compounds show enhanced oral bioavailability and increased binding to the PepT1 transporter. The present invention also provides compositions and methods for treating virus infections, and a method of preparing cidofovir.

  基于西多福韦或环状西多福韦框架的氨基酸、二肽或三肽结合的西多福韦化合物。这些化合物表现出增强的口服生物利用度和对PepT1转运体的增强结合。本发明还提供了治疗病毒感染的组合物和方法，以及制备西多福韦的方法。
• [EN] BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE<br/>[FR] BENZOPHENONES AGISSANT COMME INHIBITEURS DE LA TRANSCRIPTASE INVERSE
  申请人：GLAXO GROUP LTD

  公开号：WO2001017982A1

  公开（公告）日：2001-03-15

  The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.

  本发明包括苯甲酮化合物（I），其在治疗HIV感染方面具有用处。